News

 

At AseBio, we follow the latest news in the biotechnology sector and pass the highlights on to you. You can use the search engine to find news articles we’ve written, contributed by our members or from other stakeholders in the sector. And they are also organised into categories to help you find the topics you’re interested in easily.

Search engine
Alcohol dehydrogenase
ZYMVOL and AMINOVERSE team up to develop custom-made alcohol dehydrogenases
Antibiotic resistance
Primarily used in the Flavours & Fragrances (F&F) and Fine Chemicals industries, alcohol…
Partners - Zymvol Biomodeling
Logo de Oryzon
ORYZON to present a corporate update and to hold multiple virtual corporate activities in January-2021
The company will present recent clinical developments at the H.C. Wainwright Bioconnect, will…
oryzon
ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry
Goal is to characterize the neuropsychiatric symptoms of patients harboring disease-causing SETD1A…
José Manuel Franco and Maider Goyena after getting the prize
VIVEbiotech winner of the 2020 Gipuzkoa SME Award
Partners - VIVEbiotech
New H2020 project on ATMPs. Asphalion is the regulatory partner of the ARDAT project
New H2020 project on ATMPs. Asphalion is the regulatory partner of the ARDAT project
The European Union has awarded a grant of 25.5€ million for the Accelerating Research and…
Partners - Asphalion
Project team
We’ve been awarded a one million euro grant by the Ministry of Science to study brain tumor biomarkers with Fundación Rioja Salud and the University of the Balearic Islands
The Spanish government has announced the public grants corresponding to the State Program for…
Partners - Laminar Pharma
Logo de Oryzon
ORYZON to present further positive efficacy data from iadademstat ALICE Phase IIa trial at the 62nd Congress of the American Society of Hematology
Will also present at Jefferies 2020 Virtual London Healthcare Conference. CEO to participate…
Partners - Oryzon Genomics
ORYZON receives approval to start PORTICO Phase IIb trial with vafidemstat in Borderline Personality Disorder
ORYZON receives approval to start PORTICO Phase IIb trial with vafidemstat in Borderline Personality Disorder
Clinical Trial Application approved by Spanish Drug Agency
Oryzon announces appointment of Dr. Torsten Hoffmann as Global R&D Director and retirement of Dr. Tamara Maes
Oryzon announces appointment of Dr. Torsten Hoffmann as Global R&D Director and retirement of Dr. Tamara Maes
At Roche, Dr. Hoffmann was Head of Discovery Chemistry and Head of the Roche Postdoc Fellowship…